Statin Use, Candidate Mevalonate Pathway Biomarkers, and Colon Cancer Survival in a Population-based Cohort Study

Overview

Journal Br J Cancer

Specialty Oncology

Date 2017 May 20

PMID 28524155

Citations 27

Authors

Ronan T Gray

Maurice B Loughrey

Peter Bankhead

Chris R Cardwell

Stephen McQuaid

Roisin F ONeill

Kenneth Arthur

Victoria Bingham

Claire McGready

Anna T Gavin

Jacqueline A James

Peter W Hamilton

Manuel Salto-Tellez

Liam J Murray

Helen G Coleman

Affiliations

Soon will be listed here.

Abstract

Background: Statin use after colorectal cancer diagnosis may improve survival but evidence from observational studies is conflicting. The anti-cancer effect of statins may be restricted to certain molecular subgroups. In this population-based cohort study, the interaction between p53 and 3-hydroxy-3-methylglutaryl coenzyme-A reductase (HMGCR) expression, KRAS mutations, and the association between statin use and colon cancer survival was assessed.

Methods: The cohort consisted of 740 stage II and III colon cancer patients diagnosed between 2004 and 2008. Statin use was determined through clinical note review. Tissue blocks were retrieved to determine immunohistochemical expression of p53 and HMGCR in tissue microarrays and the presence of KRAS mutations in extracted DNA. Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for colorectal cancer-specific and overall survival.

Results: Statin use was not associated with improved cancer-specific survival in this cohort (HR=0.91, 95% CI 0.64-1.28). Statin use was also not associated with improved survival when the analyses were stratified by tumour p53 (wild-type HR=1.31, 95% CI 0.67-2.56 vs aberrant HR=0.80, 95% CI 0.52-1.24), HMGCR (HMGCR-high HR=0.69, 95% CI 0.40-1.18 vs HMGCR-low HR=1.10, 95% CI 0.66-1.84), and KRAS (wild-type HR=0.73, 95% CI 0.44-1.19 vs mutant HR=1.21, 95% CI 0.70-2.21) status.

Conclusions: Statin use was not associated with improved survival either independently or when stratified by potential mevalonate pathway biomarkers in this population-based cohort of colon cancer patients.

Citing Articles

Distinct Molecular Profiles of Sporadic Early-Onset Colorectal Cancer: A Population-Based Cohort and Systematic Review.

Hamilton A, Bannon F, Dunne P, James J, McQuaid S, Gray R Gastro Hep Adv. 2024; 2(3):347-359.

PMID: 39132649 PMC: 11307521. DOI: 10.1016/j.gastha.2022.11.005.

Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study.

Wagner S, Reisenbuchler D, West N, Niehues J, Zhu J, Foersch S Cancer Cell. 2023; 41(9):1650-1661.e4.

PMID: 37652006 PMC: 10507381. DOI: 10.1016/j.ccell.2023.08.002.

Strategies and techniques for quality control and semantic enrichment with multimodal data: a case study in colorectal cancer with eHDPrep.

Toner T, Pancholi R, Miller P, Forster T, Coleman H, Overton I Gigascience. 2023; 12.

PMID: 37171130 PMC: 10176503. DOI: 10.1093/gigascience/giad030.

Drugs Targeting p53 Mutations with FDA Approval and in Clinical Trials.

Nishikawa S, Iwakuma T Cancers (Basel). 2023; 15(2).

PMID: 36672377 PMC: 9856662. DOI: 10.3390/cancers15020429.

Statins Alleviate Tumor Hypoxia in Prostate Cancer Models by Decreasing Oxygen Consumption: An Opportunity for Radiosensitization?.

dHose D, Mignion L, Hamelin L, Sonveaux P, Jordan B, Gallez B Biomolecules. 2022; 12(10).

PMID: 36291627 PMC: 9599109. DOI: 10.3390/biom12101418.

References

Konstantinopoulos P, Karamouzis M, Papavassiliou A . Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov. 2007; 6(7):541-55. DOI: 10.1038/nrd2221. View

Goldstein J, Brown M . Regulation of the mevalonate pathway. Nature. 1990; 343(6257):425-30. DOI: 10.1038/343425a0. View

Kim B, Park S, Hong S, Cheon J, Kim W, Kim T . The effect of prediagnostic aspirin use on the prognosis of stage III colorectal cancer. Int J Clin Exp Med. 2015; 8(8):13435-45. PMC: 4612965. View

Thurnher M, Nussbaumer O, Gruenbacher G . Novel aspects of mevalonate pathway inhibitors as antitumor agents. Clin Cancer Res. 2012; 18(13):3524-31. DOI: 10.1158/1078-0432.CCR-12-0489. View

McCluggage W, Soslow R, Gilks C . Patterns of p53 immunoreactivity in endometrial carcinomas: 'all or nothing' staining is of importance. Histopathology. 2011; 59(4):786-8. DOI: 10.1111/j.1365-2559.2011.03907.x. View

Borgquist S, Jogi A, Ponten F, Ryden L, Brennan D, Jirstrom K . Prognostic impact of tumour-specific HMG-CoA reductase expression in primary breast cancer. Breast Cancer Res. 2008; 10(5):R79. PMC: 2614512. DOI: 10.1186/bcr2146. View

Ogino S, Chan A, Fuchs C, Giovannucci E . Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut. 2010; 60(3):397-411. PMC: 3040598. DOI: 10.1136/gut.2010.217182. View

Cardwell C, Hicks B, Hughes C, Murray L . Statin use after colorectal cancer diagnosis and survival: a population-based cohort study. J Clin Oncol. 2014; 32(28):3177-83. DOI: 10.1200/JCO.2013.54.4569. View

Hoffmeister M, Jansen L, Rudolph A, Toth C, Kloor M, Roth W . Statin use and survival after colorectal cancer: the importance of comprehensive confounder adjustment. J Natl Cancer Inst. 2015; 107(6):djv045. DOI: 10.1093/jnci/djv045. View

10.

Paleari L, Puntoni M, Clavarezza M, DeCensi M, Cuzick J, DeCensi A . PIK3CA Mutation, Aspirin Use after Diagnosis and Survival of Colorectal Cancer. A Systematic Review and Meta-analysis of Epidemiological Studies. Clin Oncol (R Coll Radiol). 2015; 28(5):317-26. DOI: 10.1016/j.clon.2015.11.008. View

11.

Zanders M, van Herk-Sukel M, Vissers P, Herings R, Haak H, van de Poll-Franse L . Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?. Br J Cancer. 2015; 113(3):403-10. PMC: 4522645. DOI: 10.1038/bjc.2015.259. View

12.

Krens L, Simkens L, Baas J, Koomen E, Gelderblom H, Punt C . Statin use is not associated with improved progression free survival in cetuximab treated KRAS mutant metastatic colorectal cancer patients: results from the CAIRO2 study. PLoS One. 2014; 9(11):e112201. PMC: 4223044. DOI: 10.1371/journal.pone.0112201. View

13.

Gustbee E, Tryggvadottir H, Markkula A, Simonsson M, Nodin B, Jirstrom K . Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients. BMC Clin Pathol. 2015; 15:8. PMC: 4479235. DOI: 10.1186/s12907-015-0008-2. View

14.

Ogino S, Fuchs C, Giovannucci E . How many molecular subtypes? Implications of the unique tumor principle in personalized medicine. Expert Rev Mol Diagn. 2012; 12(6):621-8. PMC: 3492839. DOI: 10.1586/erm.12.46. View

15.

Kaye P, Haider S, James P, Soomro I, Catton J, Parsons S . Novel staining pattern of p53 in Barrett's dysplasia--the absent pattern. Histopathology. 2010; 57(6):933-5. DOI: 10.1111/j.1365-2559.2010.03715.x. View

16.

Khan N, Perera R, Harper S, Rose P . Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract. 2010; 11:1. PMC: 2820468. DOI: 10.1186/1471-2296-11-1. View

17.

Kobel M, Reuss A, du Bois A, Kommoss S, Kommoss F, Gao D . The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 2010; 222(2):191-8. DOI: 10.1002/path.2744. View

18.

Brennan D, Laursen H, OConnor D, Borgquist S, Uhlen M, Gallagher W . Tumor-specific HMG-CoA reductase expression in primary premenopausal breast cancer predicts response to tamoxifen. Breast Cancer Res. 2011; 13(1):R12. PMC: 3109580. DOI: 10.1186/bcr2820. View

19.

Fumagalli D, Gavin P, Taniyama Y, Kim S, Choi H, Paik S . A rapid, sensitive, reproducible and cost-effective method for mutation profiling of colon cancer and metastatic lymph nodes. BMC Cancer. 2010; 10:101. PMC: 2845115. DOI: 10.1186/1471-2407-10-101. View

20.

Ng K, Ogino S, Meyerhardt J, Chan J, Chan A, Niedzwiecki D . Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803. J Natl Cancer Inst. 2011; 103(20):1540-51. PMC: 3196479. DOI: 10.1093/jnci/djr307. View